LONDON (Alliance News) - Summit Therapeutics PLC Monday said that preclinical data support the disease-modifying potential of utrophin modulation as a "potentially valuable mechanism" for treating Duchenne muscular dystrophy.
Professor Kay Davies of the University of Oxford, England, said the data highlight the importance of the continued development of second-generation, orally available utrophin modulator candidates.
"There is tremendous therapeutic potential for utrophin modulation in this devastating disease because there is currently no approved disease modifying therapy applicable to all patients with DMD and many other candidates in clinical development are restricted to a single mutation," Davies said.
Shares in Summit Therapeutics were up 6.0% at 154.75 pence on Monday afternoon in London.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
